0000886163-18-000042.txt : 20180306 0000886163-18-000042.hdr.sgml : 20180306 20180306183649 ACCESSION NUMBER: 0000886163-18-000042 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20180305 FILED AS OF DATE: 20180306 DATE AS OF CHANGE: 20180306 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: LAMATTINA JOHN L CENTRAL INDEX KEY: 0001216074 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-33093 FILM NUMBER: 18671346 MAIL ADDRESS: STREET 1: 81 WYMAN ST STREET 2: POST OFFICE BOX 9046 CITY: WALTHAM STATE: MA ZIP: 02454 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: LIGAND PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000886163 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 770160744 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 3911 SORRENTO VALLEY BLVD STREET 2: SUITE 110 CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 858-550-7500 MAIL ADDRESS: STREET 1: 3911 SORRENTO VALLEY BLVD STREET 2: SUITE 110 CITY: SAN DIEGO STATE: CA ZIP: 92121 4 1 edgardoc.xml PRIMARY DOCUMENT X0306 4 2018-03-05 0 0000886163 LIGAND PHARMACEUTICALS INC LGND 0001216074 LAMATTINA JOHN L 3911 SORRENTO VALLEY BOULEVARD, STE 110 SAN DIEGO CA 92121 1 0 0 0 Common Stock 2018-03-05 4 M 0 3335 10.12 A 24291 D Common Stock 2018-03-05 4 S 0 3335 160.9007 D 20956 D Non-Qualified Stock Option (right to buy) 10.12 2018-03-05 2018-03-05 4 M 0 3335 0.0 D 2021-06-01 Common Stock 3335 0 D The sale reported on this Form 4 was made pursuant to a written trading plan adopted by the Reporting Person on December 05, 2017, in accordance with Rule 10b5-1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $158.03 to $161.94, inclusive. The reporting person undertakes to provide, upon request to the Securities Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 01, 2011, and fully vested on the first anniversary of the grant date. By: Charles S. Berkman For: John L. LaMattina 2018-03-06